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Abstract
Objectives:  To  assess  bone  mineral  density  (BMD)  in  children  with  idiopathic  nephrotic  syndrome
(NS) and  normal  glomerular  ﬁltration  rate  (GFR).
Methods:  Cross-sectional  case--control  study  carried  out  on  50  children:  25  cases  of  NS  (16
steroid-sensitive  [SSNS]  and  nine  steroid-resistant  [SRNS]  under  follow  up  in  the  pediatric
nephrology  unit  of  Menouﬁa  University  Hospital,  which  is  tertiary  care  center,  were  compared
to 25  healthy  controls  with  matched  age  and  sex.  All  of  the  participants  were  subjected  to
complete  history  taking,  thorough  clinical  examination,  laboratory  investigations  (serum  creat-
inine, blood  urea  nitrogen  [BUN],  phosphorus  [P],  total  and  ionized  calcium  [Ca],  parathyroid
hormone [PTH],  and  alkaline  phosphatase  [ALP]).  Bone  mineral  density  was  measured  at  the
lumbar spinal  region  (L2--L4)  in  patients  group  using  dual-energy  X-ray  absorptiometry  (DXA).
Results:  Total  and  ionized  Ca  were  signiﬁcantly  lower  while,  serum  P,  ALP,  and  PTH  were  higher
in SSNS  and  SRNS  cases  than  the  controls.  Osteopenia  was  documented  by  DXA  scan  in  11  patients
(44%) and  osteoporosis  in  two  patients  (8%).  Fracture  risk  was  mild  in  six  (24%),  moderate  in
two (8%),  and  marked  in  three  (12%)  of  patients.
Conclusion:  Bone  mineralization  was  negatively  affected  by  steroid  treatment  in  children  with
NS.
© 2016  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  This  is  an  open
access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/
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Densidade  mineral  óssea  em  crianc¸as com  síndrome  nefrótica  idiopática
Resumo
Objetivos:  Avaliar  a  densidade  mineral  óssea  (DMO)  em  crianc¸as  com  síndrome  nefrótica
idiopática (SNI)  e  com  taxa  de  ﬁltrac¸ão  glomerular  (TFG)  normal.
Métodos:  O  estudo  transversal  de  caso-controle  foi  realizado  com  50  crianc¸as:  25  casos  de  SNI
[16 sensíveis  a  esteroides  (SNSE)  e  nove  resistentes  a  esteroides  (SNRE)  com  acompanhamento
na unidade  de  nefrologia  pediátrica  do  hospital  da  Menouﬁa  University,  centro  de  cuidados
terciário] foram  comparados  com  25  controles  saudáveis  do  grupo  de  controle  com  idade  e  sexo
equivalentes.  Todos  os  participantes  foram  submetidos  a  anamnese  completa,  exame  clínico
completo, exames  laboratoriais  [creatinina  sérica,  nitrogênio  ureico  no  sangue  (BUN),  fósforo
(P), cálcio  (Ca)  total  e  ionizado,  paratormônio  (PTH)  e  fosfatase  alcalina  (ALP)].  A  densidade
mineral óssea  foi  mensurada  na  região  da  coluna  lombar  (L2-L4)  no  grupo  de  pacientes  usando
a absorciometria  por  raio-X  de  dupla  energia  (DXA).
Resultados:  Os  níveis  de  cálcio  total  e  ionizado  eram  signiﬁcativamente  menores,  ao  passo  que
o fósforo  sérico,  a  FA  e  o  PTH  eram  maiores  em  casos  de  SNSE  e  SNRE  que  nos  controles.  A
osteopenia  foi  documentada  pelo  exame  DXA  em  11  pacientes  (44%)  e  a  osteoporose,  em  dois
pacientes (8%).  O  risco  de  fratura  era  leve  em  seis  (24%),  moderado  em  dois  (8%)  e  acentuado
em três  (12%)  dos  pacientes.
Conclusão:  A  mineralizac¸ão  dos  ossos  foi  afetada  negativamente  pelo  tratamento  com
esteroides  em  crianc¸as  com  SN.
© 2016  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Este e´ um  artigo
Open Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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hildhood  nephrotic  syndrome  (NS)  is  deﬁned  by  nephrotic-
ange  proteinuria,  generalized  edema,  hypoalbuminuria,
nd  hyperlipidemia  with  normal  renal  function.1 Idiopathic
ephrotic  syndrome  (INS)  is  the  most  frequent  renal  disease
n  children.2 Childhood  NS  typically  follows  a  relapsing-
emitting  course,  often  requiring  recurrent  courses  of
lucocorticoids  (GC),  but  with  low  systemic  inﬂammation
uring  remission.3
Bone  mass  deposition  begins  during  fetal  life  and  con-
inues  during  infancy  and  adolescence,  stabilizing  at  the
eginning  of  adulthood.4 During  childhood  and  adolescence,
keletal  modeling  results  in  sex-  and  maturation-speciﬁc
ncreases  in  bone  density.  Metabolic  bone  disease  (MBD)  is
haracterized  by  changes  in  skeletal  mineralization  due  to
oor  bone  mineral  content  (BMC).5 Children  may  be  espe-
ially  vulnerable  to  the  effects  of  GC  on  bone  formation  and
eak  bone  mass.6
Prednisone  is  the  ﬁrst-line  treatment  for  INS  to  induce
emission,  to  prevent  relapses  and  to  avoid  side  effects
f  the  disease.7 Prolonged  administration  of  prednisone
nterferes  with  growth  and  bone  mineralization,  and  has
eleterious  effect  on  basic  cellular  mechanisms  that  are
mportant  in  the  development  and  maintenance  of  bone
trength.7,8 Steroids  are  known  to  cause  osteoporosis  and
ffect  BMC  and  bone  mineral  density  (BMD)  in  children.9
lucocorticoids  have  a  suppressive  effect  on  osteoblasto-
enesis  in  the  bone  marrow  and  promote  the  apoptosis
f  osteoblasts  and  osteocytes,  thus  leading  to  decreased
one  formation.10 There  is  some  evidence  to  suggest  that
C  may  increase  bone  resorption  by  extending  the  life-
pan  of  pre-existing  osteoclasts.11 Glucocorticoids  may  also
f
t
tromote  calcium  loss  through  the  kidneys  and  gut,  and
his  negative  calcium  balance  can  itself  lead  to  increased
one  remodeling  and  osteoclastic  activity  due  to  secondary
yperparathyroidism.12
Children  with  INS  are  at  risk  for  MBD,  accompanied  by
mportant  alterations  of  mineral  and  bone  metabolism.13
Therefore,  it  was  hypothesized  that  patients  with  NS
ould  have  BMD  deﬁcits  when  compared  to  their  peers.  This
tudy  was  designed  to  determine  BMD  in  children  with  INS
nd  normal  glomerular  ﬁltration  rate  (GFR).
ethods
his  study  was  carried  out  on  50  children  after  approval
f  the  Ethical  Committee  of  Faculty  of  Medicine,  Menouﬁa
niversity,  and  a  written  consent  was  obtained  from  the
uardians  of  patients  and  controls.  Children  were  divided
nto  two  groups:
roup  I
ncluded  25  children  aged  1--15  years  who  fulﬁll  the  clinical
riteria  for  INS  (heavy  proteinuria  >  40  mg/m2/h,  hypoalbu-
inemia  <  2.5  g/L,  hypercholesterolemia  >  250  mg/dL,  and
dema)  with  normal  renal  function  (normal  glomerular  ﬁl-
ration  by  Schwartz  formula).14 Patients  with  secondary  NS,
ith  other  conditions  unrelated  to  NS  that  could  affect
one  health,  and  patients  who  received  prior  medication
or  osteoporosis  or  vitamin  D  preparations  before  or  during
he  study  were  excluded.
All  of  the  children  with  INS  were  treated  according
o  the  standard  protocol.14 The  initial  therapy  consisted
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of  daily  prednisone  60  mg/m2/day  (80  mg  daily  max)  for
four  weeks,  followed  by  40  mg/m2/day  given  every  other
day  as  a  single  daily  dose  for  at  least  four  weeks.
The  alternate-day  dose  was  then  slowly  tapered  and  dis-
continued  over  the  next  one  to  two  months.  Relapses
(proteinuria  >  40  mg/h/m2 for  three  consecutive  days  after
having  been  in  remission)  were  treated  with  60  mg/m2/day
in  a  single  morning  dose  until  the  child  entered  remis-
sion  (proteinuria  <  4  mg/m2/h  for  three  consecutive  days).
Dietary  advice  was  given  families  to  provide  their  children
a  diet  rich  in  calcium,  adequate  caloric  intake,  adequate
r
w
p
Table  1  Demographic  and  clinical  data  of  the  studied  groups.
Parameter/group  SSNS  SRNS
Number  types  16  9  
14 SDNS
2 IFRNS
Zero  FRNS
Age (years):  7.62  ±  2.78  7.78  
x¯ ± SD  
Sex: n  (%)
Male  13  (81.3)  2  (22
Female 3  (18.7)  7  (77
Weight (Z-score):  1.23  ±  1.57  1.42  
x¯ ±  SD  
Height  (Z-score):  −0.54  ±  1.35  −0.5
x¯ ± SD
BMI (Z-score): 0.76  ±  0.83  0.90  
x¯ ±  SD
Serum  creatinine  (0.3--1.5  mg/dL): 0.59  ±  0.13 0.60  
x¯ ± SD
BUN (7--22  mg/dL): 19.94  ±  4.46 20.00
x¯ ±  SD  
Total calcium  (8.8--10.8  mg/dL):  9.24  ±  0.87  9.37  
x¯ ± SD  
Ionized  calcium  (4.4--5.4  mg/dL):  1.23  ±  0.06  1.21  
x¯ ± SD  
Serum  phosphorus  (4.5--5.5  mg/dL):  5.01  ±  0.63  4.84  
x¯ ± SD  
Alkaline phosphatase  (<300  U/L):  156.81  ±  51.91  171.8
x¯ ± SD  
PTH  (9--52  pg/mL):  44.06  ±  27.69  48.78
x¯ ± SD  
SSNS, steroid-sensitive nephrotic syndrome; SRNS, steroid-resistant ne
x¯ ± SD, mean ± standard deviation; PTH, parathyroid hormone; BMI, bo
SSNS and SRNS; F2, difference between SSNS and control; F3, differenc
a p value < 0.001.
b p value < 0.05. PRESS
3
rotein  (1  g/kg/d),  with  no  added  salt  to  limit  ﬂuid  overload.
he  prednisone  dose  was  then  changed  to  alternate-day
osing  as  noted  with  initial  therapy,  and  gradually  tapered
ver  four  to  eight  weeks.  Patients  with  INS  were  clas-
iﬁed  into  three  groups  depending  on  their  response  to
C  therapy:  [i]  steroid-dependent  NS:  two  consecutive
elapses  during  corticosteroid  therapy  or  within  14  days
fter  cessation  of  therapy  (SDNS:  14  patients);  [ii]  steroid-
esistant  NS:  failure  to  achieve  remission  following  four
eeks  of  prednisone  60  mg/m2 followed  by  three  methyl-
rednisolone  pulses  (SRNS:  nine  patients);  [iii]  infrequent
 Control  F  test  Post  hoc  test
25
±  4.49  8.04  ±  3.37  0.076  F1  =  0.160
F2  =  0.26
F3  =  0.420
.2)  13  (52.0)  x2 =  0.32
.8)  12  (48.0)
±  1.01  −0.24  ±  1.32  8.09a F1  =  0.478
F2  =  4.785a
F3  =  4.453a
2  ±  1.05  −0.31  ±  1.15  0.206  F1  =  0.063
F2  =  0.829
F3  =  0.615
±  0.92  −0.34  ±  1.45  5.189a F1  =  0.369
F2  =  3.838a
F3  =  3.557a
±  0.14  0.56  ±  0.18  0.512  F1  =  0.297
F2  =  1.097
F3  =  1.223
 ±  3.35 11.56  ±  3.44  2.163  F1  =  0.057
F2  =  2.572
F3  =  2.179
±  0.74  10.18  ±  0.52  10.69a F1  =  0.130
F2  =  5.940a
F3  =  4.810a
±  0.06  5.02  ±  0.31  89.53a F1  =  0.328
F2  =  75.617a
F3  =  62.629a
±  0.32  4.62  ±  0.64  5.01b F1  =  0.961
F2  =  4.314b
F3  =  2.523
9  ±  105.39  68.00  ±  29.89  18.76a F1  =  0.913
F2  =  7.182a
F3  =  6.894a
 ±  25.31  28.48  ±  12.96  4.78b F1  =  0.781
F2  =  3.434b
F3  =  3.667b
phrotic syndrome; F, one way ANOVA test; 2, chi-squared test;
dy mass index; BUN, blood urea nitrogen; F1, difference between
e between SRNS and control.
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Table  2  Drug  received  and  DXA  scan  among  patient  groups.
Parameter/group  SSNS  SRNS  Student’s  t-test  p-Value
Drugs  received
Steroid  duration  (years)  2.55  ±  2.49  2.56  ±  1.62  0.02  0.49
Cumulative steroid  dose(mg/m2)  17,300.94  ±  17,221.76  11,570.00  ±  6,776.68  0.95  0.35
Immunosuppressive  drugs  No  (%)  No  (%)
Yes 9  (56%)  9  (100%)
No 7  (44%)  0  (0%)
DXA scan
BMD  0.61  ±  0.10  0.56  ±  0.24  0.81  0.42
Z-score −1.11 ±  1.08  −1.00  ±  0.86  0.27  0.79
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nephrotic  syndrome  participants  are  given  in  Table  3.
Osteopenia  was  documented  by  DXA  scan  in  11  patients  (44%)
(seven  SDNS,  four  SRNS),  and  osteoporosis  in  two  patients
(8%)  (two  SDNS).  Fracture  risk  was  mild  in  six  patients  (24%)
Table  3  Bone  mineral  density  and  fracture  risk  among
patient  groups.
Parameter  n  (%)
Bone  mineral  density
Average  12  (48.0)
Osteopenic  range 11  (44.0)
Osteoporotic  range  2  (8.0)
Fracture  risk
No  14  (56.0)SSNS, steroid-sensitive nephrotic syndrome; SRNS, steroid-resista
X-ray absorptiometry.
elapsers:  less  than  four  times  in  a  12-month  period  (IFR:  two
atients).14
roup  II
wenty-ﬁve  apparently  healthy  children  of  matched  age  and
ex  were  enrolled  as  a  control  group.  They  were  chosen
rom  the  outpatient  pediatric  clinic,  complaining  from  acute
ransient  illnesses.
All  patients  and  controls  were  subjected  to  complete
istory  taking,  including  type  of  treatment,  its  duration,
nd  dates  and  number  of  relapses.  The  cumulative  doses
f  prednisone  that  each  patient  received  during  therapy
ere  calculated  from  their  medical  charts.  Thorough  clinical
xamination  including  height,  weight,  and  body  mass  index
BMI)  were  recorded  and  plotted  on  World  Health  Organi-
ation  standard  deviation  curves.  Laboratory  investigations
ncluded  serum  creatinine,  blood  urea  nitrogen  (BUN,  phos-
horous  (P),  calcium  (total  and  ionized;  Ca),  parathyroid
ormone  (PTH),  and  alkaline  phosphatase  (ALP)  were  esti-
ated.
BMD  was  measured  at  the  lumbar  spinal  region  (L2--L4)  in
atients  group  using  dual-energy  X-ray  absorptiometry  (DXA)
Challenger  Envision  osteodensitometer,  DMS,  England).  BMD
as  classiﬁed  according  to  Bakr15 on  the  basis  of  BMD  Z-
core.  Scores  were  calculated  from  the  following  equation:
-score  =  (BMD  [g/cm3]  of  the  patient  ----  BMD  predicted  for
ge  and  sex/SD  for  BMD  [age,  sex,  and  height  matched]).
 patient  was  considered  osteopenic  if  the  Z-score  was
--1.0.  If  the  Z-score  was  ≤--2.5,  the  patient  was  classiﬁed
s  having  severe  osteopenia  (osteoporosis).  Chance  of  osteo-
orotic  fracture  <10%,  10--19%,  and  >20%  were  considered
ow,  medium,  and  high  risk  of  fracture,  respectively.16
tatistical  analysis
he  results  were  analyzed  statistically  using  SPSS  software
version  17;  SPSS  Inc.,  Chicago,  IL,  USA).  Statistical  analy-
is  was  performed  using  one-way  ANOVA  (F  test)  with  post
oc  test,  Student’s  t-test,  and  chi-squared  test.  Correla-
ions  were  determined  by  Pearson  correlation  and  linear
egression  analysis.  Continuous  variables  were  presented  as
ean  ±  standard  deviation,  while  for  categorical  variables,phrotic syndrome; BMD, bone mineral density; DXA, dual-energy
umbers  (%)  were  used.  Signiﬁcance  was  considered  at  p-
alue  <0.05.
esults
emographic  and  anthropometric  characteristics  of  the  par-
icipants  with  steroid-sensitive  nephrotic  syndrome  (SSNS),
teroid-resistant  nephrotic  syndrome  (SRNS),  and  the  con-
rol  groups  are  summarized  in  Table  1.  Weight  and  BMI
-scores  were  signiﬁcantly  higher  in  the  SSNS  and  SRNS
atients  than  the  controls,  with  no  signiﬁcant  difference
etween  them  regarding  the  height  Z-scores.  In  terms  of
erum  markers  of  bone  turnover,  serum  Ca  (total  and  ion-
zed)  were  signiﬁcantly  lower,  while  serum  phosphorus  and
lkaline  phosphatase  were  signiﬁcantly  higher  in  both  SSNS
nd  SRNS  patients  vs.  the  controls.  Bone  aches  were  found
n  eight  patients  (32%).
No  signiﬁcant  statistical  differences  were  found  between
SNS  and  SRNS  patients  regarding  the  drugs  received  and
XA  measurements  (Table  2).  Seventy-two  percent  of  SSNS
atients  received  immunosuppressive  drugs,  as  follows:  48%
ere  cyclosporine  therapy,  4%  on  Mycophenolate  Mofetil,  8%
n  cyclophosphamide,  and  12%  on  mixed  immunosuppressive
herapy.
Bone  mineral  density  (BMD)  and  fracture  risk  betweenMild 6  (24.0)
Moderate  2  (8.0)
Marked  3  (12.0)
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Table  4  Un-standardized  and  standardized  linear  regression  coefﬁcients  for  correlations  between  Z-score  and  some  studied
parameters.
Parameter  Un-standardized  coefﬁcients  B  Standardized  coefﬁcients  B  p-Value
Age  (years) 0.06 0.19 >0.05
BMI  0.103  0.268  >0.05
Steroid duration  (years)  0.05  0.11  >0.05
Cumulative  steroid  dose  (mg/m2)  0.12  0.23  <0.05a
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MBMI, body mass index.
a Signiﬁcant.
(one  IFRNS,  two  SDNS,  three  SRNS),  moderate  in  two  (8%)
(one  SDNS,  one  SRNS),  and  marked  in  three  (12%)  (two  SDNS,
one  SRNS).
A  signiﬁcant  statistical  correlation  was  observed  between
BMD  Z-scores  and  age  of  patients  (r  =  0.43;  p  < 0.05),
weight  Z-score  (r  =  0.56;  p  <  0.001),  height  Z-score  (r  =  0.57;
p  <  0.05),  BMI  (r  =  0.34;  p  <  0.05),  duration  (r  =  −0.46;
p  <  0.05),  and  cumulative  dose  of  GC  therapy(r  =  −0.88;
p  <  0.001).  Linear  regression  analyses  in  Table  4  show  that
the  steroid  cumulative  dose  was  the  only  signiﬁcant  inde-
pendent  risk  factor.
Discussion
Although  GCs  are  the  treatment  of  choice  for  children
with  idiopathic  NS,  obesity  and  bone  mineralization  side
effects  should  be  considered.7 In  this  study,  the  analyses
clearly  showed  an  impact  of  GCs  on  body  weight  and  BMI
in  nephrotic  syndrome  participants.  Not  surprisingly,  the
SSNS  and  SDNS  patients  had  signiﬁcantly  higher  weight  and
BMI  Z-scores  than  the  controls,  but  with  insigniﬁcant  sta-
tistical  difference  between  SSNS  and  SDNS.  Similar  results
were  reported  by  Lestari  et  al.17 and  Ribeiro  et  al.7 in
their  analyses  of  obesity  in  SSNS  and  SDNS.  The  use  of  high-
dose  and  long-term  steroids  leads  to  increased  food  intake
and  inhibited  energy  expenditure  through  stimulation  of
neuropeptide-Y  and  inhibited  release  of  corticotrophin  hor-
mone.  The  process  triggers  an  anabolic  process  and  leads  to
obesity.14 Hypocalcemia  in  patients  with  NS  reported  in  this
study  was  in  line  with  Kos¸an  et  al.18 GCs  cause  hypocalcemia
by  decreased  Ca  adsorption  from  gut  and  kidneys.7
However,  some  studies  have  reported  normal  serum  cal-
cium  levels  in  children  with  NS  due  to  increased  PTH.19
There  were  signiﬁcant  elevated  levels  of  serum  P,  ALP,
and  PTH  in  patients  with  NS  vs.  controls.  These  results
are  in  accordance  with  Pan´czyk-Tomaszewska  et  al.19 and
Esmaeeili  et  al.20 Kos¸an  et  al.18 suggested  that  GCs  indi-
rectly  affect  bone  by  reduced  intestinal  calcium  absorption
and  increased  urinary  calcium  losses.  Hyperparathyroidism
reported  in  this  study  was  likely  due  to  hypocalcemia
induced  by  GCs;  high  levels  of  PTH  are  known  to  induce
reabsorption  of  Ca  from  bone,  as  mentioned  by  Aceto
et  al.21 Bone-speciﬁc  ALP,  which  is  one  of  the  isoenzymes,
is  produced  by  osteoblasts  and  is  a  good  marker  of  bone
formation22;  it  was  higher  in  the  patients  than  in  healthy
children.  Its  increase  during  GCs  therapy  in  children  with
NS  was  also  found  by  Kos¸an  et  al.18 This  elevation  may  be
related  to  increased  bone  turnover  and  improvement  of  mas-
sive  proteinuria.
RThis  study  has  reported  adverse  effect  of  GCs  on  the  BMD;
C  therapy  was  associated  with  decreased  BMD  Z-score,
steoporosis,  and  an  increased  risk  of  fracture  in  nephrotic
yndrome  children,  with  insigniﬁcant  statistical  difference
etween  SSNS  and  SRNS.  Indeed,  linear  correlation  between
he  cumulative  dose  of  GCs  and  BMD  was  recorded.  These
esults  were  in  agreement  with  those  reported  by  Pan´czyk-
omaszewska  et  al.,19 who  concluded  that  children  with  NS
reated  with  corticosteroids  are  at  risk  of  bone  mass  loss.
lso,  Aceto  et  al.21 showed  that  GCs  reduced  BMD  Z-score  in
SNS,  and  that  BMD  Z-score  signiﬁcantly  correlates  with  the
otal  dosage  of  prednisone.
Canalis23 elucidated  that  corticosteroids  suppress  the
ifferentiation  of  osteoblastic  cells  and  enhance  the  apo-
tosis  of  mature  osteoblasts,  which  result  in  a  decrease  of
one  formation  and  loss  of  BMD.  It  has  also  been  reported
hat  steroid  therapy  can  cause  osteoporosis  or  exacerbate
 pre-existing  osteoporotic  condition,  leading  to  pathologic
ractures.24 Basiratnia  et  al.25 concluded  that  bone  loss  can
ccur  in  some  steroid-dependent  nephrotic  patients,  espe-
ially  those  with  a  higher  cumulative  dose  of  steroid;  higher
umulative  doses  were  associated  with  more  steroid  con-
umption  and  consequently  more  bone  loss.
It  was  concluded  that  osteopenia  assessed  by  DXA  was
requent  in  children  with  NS,  especially  those  administered
igher  doses  of  steroids  (SDNS  or  SRNS).  Bone  mineraliza-
ion  was  negatively  affected  by  steroid  treatment  in  children
ith  NS.  The  present  study  had  some  limitations,  such  as  the
mall  number  of  patients  and  short  duration  available  for
he  study.  Therefore,  the  authors  recommend  further  stud-
es  with  a  larger  sample  size  and  longer  duration.  Regular
MD  evaluation  should  be  performed  on  NS  children,  and  an
ppropriate  therapeutic  approach  should  be  planned.
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